

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. PTO/SB/21 (08-00)
U.S. Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/876,478
	Filing Date	06/07/2001
	First Named Inventor	John A. Peyman
	Group Art Unit	1646
	Examiner Name	
Total Number of Pages in This Submission		4
Attorney Docket Number		JP-001


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	19 non-patent literature documents
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	John A. Peyman
Signature	<i>John Peyman</i>
Date	11/06/2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 11/06/2001			
Typed or printed name	John A. Peyman		
Signature	<i>John Peyman</i>	Date	11/06/2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/876,478
Filing Date	06/07/2001
First Named Inventor	John A. Peyman
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	JP-001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BINDER, L. et al. "Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties" Mol. Endocrinol. 4: 1060-1068 (1990).	
		BYATT, J. C. et al. "Stimulation of mammogenesis and lactogenesis by recombinant bovine placental lactogen in steroid-primed dairy heifers" J. Endocrinol. 140: 33-43 (1994).	
		CUNNINGHAM, B. C. and WELLS, J. A. "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis" Science 244: 1081-1085 (1989).	
		FORSYTH, I. A. "Comparative aspects of placental lactogens: structure and function" Exp. Clin. Endocrinol. 102: 244-251 (1994).	
		FREEMARK, M. et al. "A unique placental lactogen receptor: implications for fetal growth" Endocrinol. 120: 1865-1872 (1987).	
		GERTLER, A. et al. "Preparation, purification, and determination of the biological activities of 12 N terminus-truncated recombinant analogues of bovine placental lactogen" J. Biol. Chem. 267: 12655-12659 (1992).	
		GOFFIN, V. et al. "Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals" Endocrine Rev. 17: 385-410 (1996).	
		GOLOS, T. G. et al. "Cloning of four growth hormone/chorionic somatomammotropin-related complementary deoxyribonucleic acids differentially expressed during pregnancy in the rhesus monkey placenta" Endocrinol. 133: 1744-1752 (1993).	
		HAMMERSTROM, L. et al. "The immunodepressive effect of human glucoproteins and their possible role in the nonrejection process during pregnancy" Acta Obstet. Gynecol. Scand. 58: 417-422 (1979).	
		LOWMAN, H. B. et al. "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen" J. Biol. Chem. 266: 10982-10988 (1991).	
		LUCK, D. N. et al. "Bioactive recombinant methionyl bovine prolactin: structure-function studies using site-specific mutagenesis" Mol. Endocrinol. 3: 822-823 (1989).	

Examiner
Signature


Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office, U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/876,478
Filing Date	06/07/2001
First Named Inventor	John A. Peyman
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	JP-001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MISRA-PRESS, A. et al. "Complex alternative splicing partially inactivates the human chorionic somatomammotropin-like (hCS-L) gene" J. Biol. Chem. 269: 23220-23229 (1994).	
		NG, F. M. et al. "Insulin potentiating action of synthetic peptides relating to the amino terminal sequence of human growth hormone" Diabetes 23: 943-949 (1974).	
		ORMANDY, C. J. "Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse" Genes Dev. 11:167-78 (1997).	
		REDLINE, R. W. and PATTERSON, P. "Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast" Hum. Pathol. 26: 594-600 (1995).	
		STEPHENSON, M. D. "Frequency of factors associated with habitual abortion in 197 couples" Fertil. Steril. 66: 24-29 (1996).	
		STRASBURGER, C. J. et al. "Indication of different lactogen and somatogen binding sites in the human growth hormone molecule as probed with monoclonal antibodies" Mol. Cell. Endocrinol. 67: 55-62 (1989).	
		STRUMAN, I. et al. "Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis." Proc. Natl. Acad. Sci. U.S.A. 96: 246-1251 (1999).	
		TAKEDA, T. et al. "Participation of JAK, STAT and unknown proteins in human placental lactogen-induced signaling: a unique signaling pathway different from prolactin and growth hormone" J. Endocrinol. 153: R1-3 (1997).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231